Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.…
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Tumble 7% for Week
Takeda Pharmaceutical (NYSE: TAK) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 47,029 employees.
The shares were at 21.77 USD on 20 November 2026, up 54.5% over 52 weeks. Its 52-week range is 14.01 USD to 22.07 USD: the price is 1.3% below the high and 55.4% above the low.
At a market capitalisation of 69.55B USD, it trades at 311.0 times trailing earnings and 41.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 1169% for TAK. It pays a dividend yielding 2.88%, against a median of 1.91% among the dividend payers in that peer group.
Takeda Pharmaceutical reports return on equity of -2.1%, an operating margin of 16.6% and revenue up 6.7% year over year.
Its debt exceeds its cash by 4.94T JPY, a debt-to-equity ratio of 0.66. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 24.67 USD is 13.3% above the current price. The next earnings report is expected on 28 January 2027.